BIO-TECHNE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77.31 USD | +2.26% |
|
+20.68% | +0.19% |
| May. 02 | UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating | MT |
| May. 02 | Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85 | MT |
Presenter SpeechValerie Dixon (Analysts)Hi everybody. We'll get started. Good afternoon. My na...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows:
- biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.;
- diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc.
Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Calendar
2024-08-05
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
75.6
USD
Average target price
83
USD
Spread / Average Target
+9.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.19% | 11.88B | |
| +25.64% | 48.09B | |
| +46.90% | 40.62B | |
| -3.46% | 40.43B | |
| -6.20% | 28.36B | |
| +9.17% | 24.89B | |
| -20.42% | 19.01B | |
| +28.06% | 12.09B | |
| -1.24% | 11.8B | |
| +19.35% | 11.45B |
- Stock Market
- Equities
- TECH Stock
- News Bio-Techne Corporation
- Transcript : Bio-Techne Corporation Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 01
